financetom
Business
financetom
/
Business
/
Vivani Medical Completes Enrollment, Begins Dosing in Diabetes Implant Trial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vivani Medical Completes Enrollment, Begins Dosing in Diabetes Implant Trial
Mar 13, 2025 5:50 AM

08:26 AM EDT, 03/13/2025 (MT Newswires) -- Vivani Medical ( VANI ) said Thursday that it has completed enrolling participants in its initial clinical trial testing NPM-115, a subdermal GLP-1 implant for overweight adults with type 2 diabetes.

The company said the first patient received the implant as part of the study, which is designed to evaluate drug absorption and safety over a six-month period.

Vivani said the enrollment concluded about four weeks after the first subject was dosed, with preliminary results expected by mid-2025.

The company's shares were up more than 2% in recent Thursday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved